Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights.
Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights:
- Research Methodology
- Global & Regional Transdermal Path Market Outlook
- Global Transdermal Patch Market Opportunity > USD 20 Billion
- Clinical Trials Insight By Company, Indication, Drug Molecule & Phase
- Comprehensive Insight On 60 Transdermal Patch Available Commercially
- Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase
- Transdermal Patch Dosage & Price Availability By Indication
- Competitive Landscape
Download Report:
https://www.kuickresearch.com/report-global-transdermal-patch-market
Oral route of drug delivery is one of the most accepted routes of drug delivery system. However, this route of delivery is associated with several limitations including non-specificity and inactivation while passing through gastrointestinal tract and inability to provide the sustained effect. To overcome this, researchers have developed transdermal drug delivery which is an easy, painless, and convenient mode of application. The transdermal patches developed are the medicated adhesive patch that is placed on skin to deliver a specific dose of medication. These patches deliver a medication dose through the skin using a diffusion technique, which is later released in the blood stream over a long period of time.
To date, more than 50 transdermal patches have been approved globally which have been indicated for the management of several diseases including migraine, hormones, pain, cardiovascular diseases, neurological disorders, and smoking cessation. Nicotine patches which delivers nicotine into the body is currently dominating the market. This patch is usually used to help prevent nicotine cravings that smokers experience when trying to quit smoking. The nicotine patch segment is going to expand during the forecast period due to an increase in population willing to quit smoking and rising awareness about the availability of nicotine patch.
The pharmaceutical companies are well aware of their importance and acceptance by the consumers therefore they are continuously researching to make their better analogues. Recently, PharmaTher Holdings and TSRL entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs. Furthermore, AMW and Adhex Pharma announced strategic partnership for the development of transdermal patches. The rising collaboration, partnerships, and joint ventures among the pharmaceutical companies will propel the growth of market during the forthcoming years.
The global prevalence of COVID-19 has surged the demand of vaccination. . Although more than 2 Billion people worldwide are fully vaccinated but many who live in resource-limited countries haven’t been able to get vaccines, partly because these areas lack temperature controlled shipping and storage facilities. Recently, researchers in ACS Nano have developed a microneedle patch which delivers a COVID-19 DNA vaccine into the skin, causing strong immune responses in cells and mice. More importantly, these patches can be stored for over 30 days at room temperature. More recently, a UK company Emergex has developed a new COVID-19 vaccine intended to be delivered via a skin patch with microneedles has been granted approval for human trials.
It has only been few years since the entry of transdermal patches in global market, but these have shown high adoption rates which can be justified by their robust sales in the market. In addition, supportive healthcare policies, large number of patients and a developed healthcare market also propels the growth of market. Further, major companies in global market are increasingly opting for acquisitions and collaborations to enhance and expand their footprint for the growth of the transdermal skin patches, which will further propel the growth of market during forecast period. As per our report finding, the global transdermal patch is expected to surpass US$ 20 Billion by 2028.
The global transdermal patch market report provides insights into globally approved transdermal patches on the basis of their indication. The report provides comprehensive information about the transdermal patches pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The report reviews details of major pipeline products which include, product description, licensing and collaboration details and other developmental activities. The key players mentioned in report include 3M Pharmaceutical, Purdue Pharma, Sanofi, Ipsen Bioscience, Hisamitsu Pharmaceutical, Fempharm, Allergan, and several others.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com